Psammaplysene D overcomes sorafenib resistance in liver cancer by targeting FGFR4/CYP26A1-retinoic acid axis to drive ferroptosis
Overall, Psammaplysene D is a potent therapeutic agent for liver cancer, effective alone or combined with sorafenib, and overcomes resistance through direct targeting of FGFR4, initiating a cascade of CYP26A1 downregulation, RA accumulation, and ferroptosis induction-defining a novel FGFR4/CYP26A1/RA axis regulating ferroptosis in resistant liver cancer.
Authors
- R. H. Li
- Ting Yang (ORCID: https://orcid.org/0000-0002-5113-8611)
- X X Li
- Yanlu Han
- Jinbo Yang (ORCID: https://orcid.org/0000-0003-3517-9701)
- Xiaonan Zhang (ORCID: https://orcid.org/0000-0003-4359-9079)
- X. George Xu
- Yuting Wang
- Xinxin Zhang
- Wen Wang
- Jing Xu
- Chunhua Lin
Institutions
- Qingdao University (CN)
- Yuhuangding Hospital (CN)
- Affiliated Hospital of Qingdao University (CN)
- Marine Biomedical Research Institute of Qingdao (CN)
- Qilu Hospital of Shandong University (CN)
- Ocean University of China (CN)
Publication Details
- Journal
- Journal of Experimental & Clinical Cancer Research
- Published
- 2026-01-06
- DOI
- https://doi.org/10.1186/s13046-025-03622-1
- Citations
- 1
- Primary Topic
- Ferroptosis and cancer prognosis
- Type
- article
- Field-Weighted Citation Impact
- 36.44